SEC Company Response from IRADIMED CORP (IRMD) (CIK 0001325618) (IRMD) — Jul 11, 2014
IRADIMED CORP (IRMD) (CIK 0001325618)
Date: July 11, 2014 · CIK: 0001325618 · Accession: 0001104659-14-051245
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-196875
Referenced dates: July 9, 2014
Letter
VIA EDGAR
July 11, 2014
Amanda Ravitz
Assistant Director
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street NE
Washington, DC 20549
Re: Iradimed Corporation Registration Statement on Form S-1 File No. 333-196875
Ladies and Gentlemen:
Roth Capital Partners, LLC as representative for Monarch Capital Group (the “Underwriters”) respectfully joins the request of Iradimed Corporation (the “Company”), that the Commission accelerate the effective date of the Company’s Registration Statement on Form S-1, File No. 333-196875, as amended, to 4:30 pm Eastern time on Tuesday, July 15, 2014, or as soon thereafter as practicable.
In addition, the Underwriters hereby provide the Staff with supplemental information regarding the distribution of the preliminary prospectus dated July 9, 2014 as filed with the Commission on July 9, 2014.
The following is supplemental information supplied under Rule 418(a)(7) and Rule 460 under the Securities Act of 1933:
(i) Date of preliminary prospectus: July 9, 2014
(ii) Dates of distribution: July 9, 2014 to July 11, 2014
(iii) Number of prospective underwriters and dealers to whom the preliminary prospectus was furnished: 9
(iv) Number of prospectuses distributed to underwriters, dealers and other potential participants in the above-referenced issue: approximately 557
In addition to the foregoing, the undersigned (x) distributed on July 9, 2014, an electronic copy of the preliminary prospectus to each underwriter and dealer participating in the above-referenced issue; and (y) instructed each such dealer to distribute such preliminary prospectus to each of its customers who may participate in the above-referenced issue.
The undersigned confirms that they have complied with and will continue to comply with, and they have been informed or will be informed by participating dealers that they have complied with or will comply with, Rule 15c2-8 promulgated under the Securities Exchange Act of 1934, as amended, in connection with the above-referenced issue.
Very truly yours,
ROTH CAPITAL PARTNERS, LLC
Show Raw Text
CORRESP 1 filename1.htm VIA EDGAR July 11, 2014 Amanda Ravitz Assistant Director United States Securities and Exchange Commission Division of Corporation Finance 100 F Street NE Washington, DC 20549 Re: Iradimed Corporation Registration Statement on Form S-1 File No. 333-196875 Ladies and Gentlemen: Roth Capital Partners, LLC as representative for Monarch Capital Group (the “Underwriters”) respectfully joins the request of Iradimed Corporation (the “Company”), that the Commission accelerate the effective date of the Company’s Registration Statement on Form S-1, File No. 333-196875, as amended, to 4:30 pm Eastern time on Tuesday, July 15, 2014, or as soon thereafter as practicable. In addition, the Underwriters hereby provide the Staff with supplemental information regarding the distribution of the preliminary prospectus dated July 9, 2014 as filed with the Commission on July 9, 2014. The following is supplemental information supplied under Rule 418(a)(7) and Rule 460 under the Securities Act of 1933: (i) Date of preliminary prospectus: July 9, 2014 (ii) Dates of distribution: July 9, 2014 to July 11, 2014 (iii) Number of prospective underwriters and dealers to whom the preliminary prospectus was furnished: 9 (iv) Number of prospectuses distributed to underwriters, dealers and other potential participants in the above-referenced issue: approximately 557 In addition to the foregoing, the undersigned (x) distributed on July 9, 2014, an electronic copy of the preliminary prospectus to each underwriter and dealer participating in the above-referenced issue; and (y) instructed each such dealer to distribute such preliminary prospectus to each of its customers who may participate in the above-referenced issue. The undersigned confirms that they have complied with and will continue to comply with, and they have been informed or will be informed by participating dealers that they have complied with or will comply with, Rule 15c2-8 promulgated under the Securities Exchange Act of 1934, as amended, in connection with the above-referenced issue. Very truly yours, ROTH CAPITAL PARTNERS, LLC By: /s/ Aaron Gurewitz Name: Aaron Gurewitz Title: Head of Equity Capital Markets For itself and as the Representative of the several Underwriters. cc: Mary Beth Breslin, Securities and Exchange Commission Brian Soares, Securities and Exchange Commission Michael J. Kinkelaar, Esq., Procopio, Cory, Hargreaves & Savitch LLP Leib Orlanski, Esq., K&L Gates LLP Anh Q. Tran, Esq., K&L Gates LLP 2